Veracyte (VCYT) Tmuɣli n wazal
Veracyte
Ṛṛbem n lḥedd$45.45Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-6.39%
Asnulfu n AI: VCYT
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Veracyte, Inc. develops molecular tests for cancer. The company offers molecular cytology and validates the accuracy of diagnostic results from cytological samples. Veracyte provides its products and services to healthcare and molecular diagnostics companies in the United States.
